Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;9(12):1715-25.
doi: 10.1586/era.09.153.

Bevacizumab and breast cancer: current therapeutic progress and future perspectives

Sherry X Yang  1
Affiliations
Review

Bevacizumab and breast cancer: current therapeutic progress and future perspectives

Sherry X Yang. Expert Rev Anticancer Ther. 2009 Dec.

Abstract

Bevacizumab is a humanized monoclonal antibody to VEGF, and the incorporation of bevacizumab to chemotherapy is one of the rapidly evolving areas in the treatment of breast cancer. Bevacizumab in combination with chemotherapy versus chemotherapy alone improves progression-free survival and increases the response rate in first-line therapy for locally recurrent or metastatic breast cancer. This approach has been and is still being evaluated for early breast cancer in neoadjuvant and adjuvant settings. Bevacizumab is well tolerated and has an established tolerability profile. Both tumor- and host-related biomarkers of bevacizumab activity, response and benefit are emerging from Phase I, II and III clinical trials. The biomarkers of benefit will ultimately help identify the subgroups of patients who specifically benefit from anti-VEGF therapy with bevacizumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971;285(21):1182–1186. - PubMed
    1. Kaelin WG., Jr. The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem. Biophys. Res. Commun. 2005;338(1):627–638. - PubMed
    1. Ruohola JK, Valve EM, Karkkainen MJ, et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol. Cell. Endocrinol. 1999;149(1–2):29–40. - PubMed
    1. Mueller MD, Vigne JL, Minchenko A, et al. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors α and β. Proc. Natl Acad. Sci. USA. 2000;97(20):10972–10977. - PMC - PubMed
    1. Klos KS, Wyszomierski SL, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 2006;66(4):2028–2037. - PubMed

MeSH terms

Substances